Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Acute Lymphoblastic Leukemia (Jun 2019)

Posted by Matt Breese on Jun 28, 2019

Find me on:

According to our recent payer coverage analysis for acute lymphoblastic leukemia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for acute lymphoblastic leukemia treatments shows that under the pharmacy benefit, about 42% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Acute Lymphoblastic Leukemia_2Q2019-finalData snapshot as of Q2 2019

Trends: Kymriah is the first FDA-approved CAR-T cell therapy indicated for patients up to 25 years of age with relapsed or refractory B-cell ALL. Most payers list Kymriah as a drug that needs prior authorization, because a number of restrictions exist when using this medication.

To read the full Reality Check on Acute Lymphoblastic Leukemia treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing